Skip to main content

Economic Aspects of Death and Dying in Oncology

  • 928 Accesses

Abstract

The study of economic issues relevant to oncology, death, and dying is – and should be – an important component of a multifaceted analysis of our healthcare system. This includes the analysis and design of practices and policies of healthcare providers and individual physician and patient-consumer decision-making processes.

Keywords

  • Gross Domestic Product
  • Moral Hazard
  • Quality Adjusted Life Year
  • Adverse Selection
  • Health Insurance Program

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Notes

  1. 1.

    National health expenditures includes health consumption expenditure (inclusive of personal health care, administration and net cost of private health insurance, and public health spending), as well as investment in health care.

  2. 2.

    Per OECD methodology, the United States spends 16.4 % of its GDP on healthcare in 2013, rather than 17.4 %, as calculated by the US National Center for Health Statistics.

  3. 3.

    Direct medical costs of cancer treatment are generally U-shaped. The spikes in direct costs are associated with initial period following the diagnosis and end-of-life period; and direct costs are typically lowest in the period between the two, as in the case of colorectal cancers of varying survival rates (Yabroff et al. 2008).

References

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vlad Dolgopolov .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Dolgopolov, V. (2017). Economic Aspects of Death and Dying in Oncology. In: Berk, L. (eds) Dying and Death in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-41861-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-41861-2_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-41859-9

  • Online ISBN: 978-3-319-41861-2

  • eBook Packages: MedicineMedicine (R0)